Abstract: The present invention is directed to the expression and secretion recombinant SARS-CoV-2 spike protein subunits. Various subunits have been designed and expressed as secreted products into the culture medium of transformed insect cell lines. The design of subunits is focused on the production of products that provide the ability to induce focused immune responses without inducing immune enhancing responses. The expressed and purified products are suitable as vaccine candidates to protect against disease caused by SARS-CoV-2.

Abstract: The present invention is directed to the expression and secretion the Zika virus envelope protein. Elements of the pre-membrane and envelope sequence have been modified to enhance the expression of the envelope protein as a secreted product in the culture medium of transformed insect cell lines. The expressed and purified product is suitable as a vaccine antigen.

Abstract: The present invention is directed to the expression and secretion the Zika virus envelope protein. Elements of the pre-membrane and envelope sequence have been modified to enhance the expression of the envelope protein as a secreted product in the culture medium of transformed insect cell lines. The expressed and purified product is suitable as a vaccine antigen.

Abstract: A West Nile virus (WNV) vaccine for human use is described that contains a recombinantly produced form of truncated WNV envelope glycoprotein and a combination of a Toll-like receptor 4 (TLR-4) and saponin adjuvants. A pharmaceutically acceptable vehicle may also be included in the vaccine.

Abstract: A West Nile virus (WNV) vaccine for human use is described that contains a recombinantly produced form of truncated WNV envelope glycoprotein and a combination of a Toll-like receptor 4 (TLR-4) and saponin adjuvants. A pharmaceutically acceptable vehicle may also be included in the vaccine.

Abstract: Recombinant subunit proteins derived from the MSP-1 C-terminal region of the parasite Plasmodium falciparum are described that have enhanced immunogenic properties. Selected regions of p33 have been combined with p19 to enhance the immunogenic potential of the p19 core region. As the constructs represent discontinuous segments fused to create unique proteins, the recombinant proteins expressed are not found in nature. The enhanced immunogenic potential of the disclosed recombinant proteins provided for strong, consistent and specific antibody responses. The disclosed recombinant subunit proteins are vaccine candidates for protection against infection with malaria.

Abstract: Filovirus subunit protein immunogens are produced using a recombinant expression system and combined with one or more adjuvants in immunogenic formulations. The subunit proteins include GP95, GP-FL, VP40, VP24, and NP derived from Ebola Virus and Marburg Virus. Adjuvants include saponins, emulsions, alum, and dipeptidyl peptidase inhibitors. The disclosed immunogenic formulations are effective in inducing strong antibody responses directed against individual Filovirus proteins and intact Filovirus particles as well as stimulating cell-mediated immune responses to the Filoviruses.

Abstract: A vaccine or immunogenic composition is described that contains recombinantly produced, secreted, forms of malaria MSP-1 C-terminal subunit proteins from any of the Plasmodium falciparum strains as active ingredients combined with one or more adjuvants. The immunogenic compositions that result in a protective response are based on the use of a single adjuvant that forms an emulsion or use of such emulsion in combination with a second adjuvant that is an immunomodulating agent. Such a vaccine elicits a strong immune response characterized by antibodies that are capable of inhibiting parasite growth in vitro as well as antibodies that are incapable of inhibiting parasite growth in vitro, but are capable of enhancing the activity of the inhibitory antibodies. The disclosed vaccine formulations are capable of generating a protective response against malaria in vaccinated subjects.

Abstract: An operator driven, ridable carpet cleaning machine is provided with a pressurized cleaning solution spray applicator located forward of a counter-rotating pair of cylindrical brushes and a pair of articulating vacuum shoes. The pressurized spray enables the delivery of sufficient cleaning solution, with agitation of the soft, carpeted surface enhanced by the counter-rotating brushes. Articulation of the vacuum shoes enables them to remain in close contact with the carpeting, maximizing the removal of the applied cleaning solution.

Abstract: The present invention provides truncated HCV E2 polypepides. The invention HCV E2 polypeptides lack the HVR1 region that provides immune protection against HCV. The present invention also provides immunogenic compositions of such polypeptides and the methods of use thereof.

Abstract: The present invention provides truncated HCV E2 polypepides. The invention HCV E2 polypeptides lack the HVR1 region that provides immune protection against HCV. The present invention also provides immunogenic compositions of such polypeptides and the methods of use thereof.

Abstract: A vaccine contains at least one Drosophila cell-secreted, recombinantly-produced form of a truncated Flavivirus envelope glycoprotein, as an active ingredient, and an adjuvant, as a critical component of the vaccine. The adjuvant is an immunomodulating agent having an iscom-like structure and comprising within the iscom-like structure at least one lipid and at least one saponin, and a pharmaceutically acceptable vehicle. Such a vaccine protects a subject against infection by a Flavivirus.

Abstract: A recombinant DNA encoding coffee bean &agr;-galactosidase permits the production of purified forms of this protein. The protein is useful in converting human Type B red blood cells into cells physiologically similar to Type O red blood cells. The availability of this enzyme permits more effective conversion than use of &agr;-galactosidase from other sources.